Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. Among authors: pan y. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
The screening of volatile markers for hepatocellular carcinoma.
Qin T, Liu H, Song Q, Song G, Wang HZ, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD. Qin T, et al. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2247-53. doi: 10.1158/1055-9965.EPI-10-0302. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20826831
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Hu XC, et al. Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795409 Clinical Trial.
Chinese guidelines on the management of renal cell carcinoma (2015 edition).
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written; CSCO Renal Cell Carcinoma Committee. Guo J, et al. Among authors: pan y. Ann Transl Med. 2015 Nov;3(19):279. doi: 10.3978/j.issn.2305-5839.2015.11.21. Ann Transl Med. 2015. PMID: 26697439 Free PMC article. Review. No abstract available.
Chinese guidelines on the management of renal cell carcinoma (2015 edition).
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written on behalf of CSCO Renal Cell Carcinoma Committee. Guo J, et al. Among authors: pan y. Chin Clin Oncol. 2016 Feb;5(1):12. doi: 10.3978/j.issn.2304-3865.2015.11.01. Chin Clin Oncol. 2016. PMID: 26932436 Free article. No abstract available.
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Zhu Y, Du Y, Liu H, Ma T, Shen Y, Pan Y. Zhu Y, et al. Among authors: pan y. Thorac Cancer. 2016 Nov;7(6):663-669. doi: 10.1111/1759-7714.12384. Epub 2016 Aug 24. Thorac Cancer. 2016. PMID: 27755796 Free PMC article. Clinical Trial.
18,453 results
You have reached the last available page of results. Please see the User Guide for more information.